RecruitingNCT07544862
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
A Prospective Study of Stapokibart Injection in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
Sponsor
Chengdu Kangnuoxing Biopharma,Inc.
Enrollment
1,000 participants
Start Date
Jun 2, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a biological treatment called Stapokibart for people with atopic dermatitis (ad). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALStapokibart
subcutaneous injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07544862
Related Trials
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT0729839523 locations
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
NCT074555782 locations
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
NCT0710548888 locations
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
NCT074536021 location
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
NCT074117551 location